Alligator Bioscience (ATORX) investor relations material

Executive summary

• Strategic pivot to focus on financial interest in HLX22, discontinuing independent development of mitazalimab due to paradigm-shifting advances in KRAS/RAS inhibitor therapies for pancreatic cancer and funding constraints.

• Ongoing wind-down of operations and cost base reduction, with a lean organization maintained to oversee HLX22 and fulfill listed company obligations.

• Rights issue of up to SEK 225 million approved (with SEK 125.6 million announced in Q2 2026) to secure operations until expected HLX22 commercialization.

Financial highlights

• General operating expenses trending below SEK 15–20 million estimate for 2026.

• SEK 16.6 million in cash at end of June 2026, with bridge financing raised in July.

• Net sales for Q2 2026 were SEK 514 thousand, with an operating loss of SEK -36.2 million and a net loss of SEK -37.8 million.

• R&D costs for the quarter were SEK 19.7 million, representing 54% of operating costs.

• No provisions yet made for wind-down costs of mitazalimab; these will impact Q3/Q4 2026 and possibly 2027.

Outlook and guidance

• Fully subscribed rights issue expected to fund operations until HLX22 launch, with first royalty revenues anticipated in 2030.

• Net proceeds intended to preserve HLX22 royalty potential, fund wind-down of mitazalimab, and secure financing until topline Phase 3 HLX22 data in 2027.

• No further proprietary drug development planned; focus is on out-licensing or divesting remaining assets.